Today, we pause to pay tribute and honor the brave heroes who have made the ultimate sacrifice while serving in the armed forces.

Today the FDA’s Medical Devices Advisory Committee panel strongly recommended FDA approval of our Shield blood test for #ColorectalCancer screening in adults age 45 and older who are at average risk for the disease.

Full release: investors.guardanthealth.com/press-releases…

ICYMI: UC San Diego Professor of Medicine Samir Gupta, MD discusses how new screening options, such as our Shield blood test, could help elevate #ColorectalCancer screening rates, identify treatable cancers, and reduce the number of deaths from the disease.

Today we announced an important achievement: EU IVDR certification for our Guardant360 CDx blood test.

Co-CEO Helmy Eltoukhy noted, “The IVDR certification for the Guardant360 CDx liquid biopsy is a significant milestone for cancer care in the EU...'

investors.guardanthealth.com/press-releases…

Following our milestone announcement of 500 peer-reviewed publications, we sat down with our Chief Medical Officer Dr. Craig Eagle to discuss the significance of the achievement along with the impact on #PatientCare .

Watch the full Q&A: youtu.be/oWO_Xr3FsjA?si…

We look forward to presenting data from two real-world studies at the 2024 Digestive Disease Week in Washington, DC, highlighting the value of our Shield test for #ColorectalCancer screening.

More details: investors.guardanthealth.com/press-releases…

Our Co-CEO's Helmy Eltoukhy and AmirAli Talasaz joined leaders from around the world at the Milken Institute 2024 Global Conference.

Among the sessions they participated in was “The Cancer Diagnostics Revolution”, exploring innovative cancer-screening technologies.

#MIGlobal

Our Co-CEO AmirAli Talasaz caught up with FierceBiotech at the Milken Institute Global Conference where he discussed our upcoming FDA advisory panel review for Shield, our blood-based screening test for #ColorectalCancer .
fiercebiotech.com/medtech/guarda…

A breathtaking sight over our laboratory in Redwood City.

#AuroraBorealis #NorthernLights

Today, we announced our first quarter financial results and updated guidance for the year.

Full release: investors.guardanthealth.com/press-releases…

Great event highlighting the future of #Cancer care. Thank you John Joyce, M.D. for mentioning blood based CRC screening tests and to Danielle Carnival for your work with the #Cancer Moonshot.

We're honored to (again) be certified as a #GreatPlaceToWork ! This recognition is a testament to our people, who dedicate themselves to foster our diverse, inclusive and mission-driven culture.

Join us: guardanthealth.com/careers/

#GPTWcertified

Triumphant Warrior is warming the feet - and hearts - of patients at UT Health Austin’s Surgical Oncology Clinic through the gift of fun socks, which were distributed by Guardant Health! Learn more about the Surgical Oncology Clinic care team: uthealthaustin.org/clinics/cancer…

This morning we announced that our research has reached a new milestone: 500 peer-reviewed publications featuring Guardant's technology in esteemed scientific journals.

Full release: investors.guardanthealth.com/press-releases…

We're honored to be recognized by the #BidenCancerMoonshot and look forward to partnerships with the Cancer Cabinet and key stakeholder groups like First Ladies Health + Ballad Health to help close the screening gap by ensuring access to new screening tech.

bit.ly/4biXay3

Come visit us at the upcoming #ISPORAnnual from May 5 - 8 in Atlanta, where we will share four posters highlighting our GuardantINFORM real-world clinical-genomic database.

Our co-CEO Helmy Eltoukhy participated tonight in STAT in DC: Policy in Health Care, where he discussed the role of liquid biopsies in closing the gap in cancer care and the essential need for collaboration to overcome regulatory & reimbursement challenges for emerging tech.

The CRC community lost a true champion today. Donald Payne Jr. never stopped advocating on behalf of patients for policies that helped drive innovation and access. Thank you for your leadership and may you rest in peace.

Join our SVP of Global Public Affairs Jenn Higgins for a powerful discussion on the stigmas surrounding #LungCancer and the importance of equitable access to care pathways in partnership with Lung Cancer Policy Network and Lung Ambition Alliance.

▶️ : youtube.com/watch?v=WD2_NF…

Earlier today we announced an FDA advisory panel meeting to review our premarket approval application for our Shield blood test is scheduled for May 23rd.

Read more: investors.guardanthealth.com/press-releases…